Pogo's Final Stages of Stem Cell Treatment MOBILE, Ala. (WPMI) A dog we first told you about last month is in his final stages of stem cell treatment.Pogo went under the knife Friday. After 12 years o... By: Local15 … Continue reading →

GERMANY (MindaNews/15 October) This is a follow up report on my last published article about our return trip to VILLA MEDICA in Edenkoben, Germany for our familys continuing search for ways to cure my wife Beths ailing kidneys by trying the unorthodox treatment using fresh stem cells. If you recall, we went for the first time last November 2012 resulting to her kidneys recovering a bit but still not within safe levels. Hence this2nd visit buoyed by the modest improvementalmost one year after the first injections. Day 1, Monday wearrived with some Davao friends on the same flight from Manila on board ETIHAD AIRLINE after a 14-hour flight with a brief stopover at Abu Dhabi. It was cold and chilly but VILLA MEDICAs luxurious Mercedes Benz van (with a built- in wine bar to boot) made the one and a half hour land trip along Germanys famous auto-bahn highway a pleasurable zippassing through verdant green landscapes that were starting to turngoldendue to the onset of autumn. We arrived at the Regenerative Clinic on time for a mid-morning breakfast andmet upwith the rest of the group mostly from Davao arriving from other airlines. They were there trying for the first time … Continue reading →

Orange, CA (PRWEB) October 15, 2013 The leading West Coast stem cell clinic, TeleHealth, is now offering stem cell injections and regenerative medicine treatments for back pain and degenerative disc disease. Treatments involve adult stem cells, platelet rich plasma therapy and prolotherapy to help regenerate arthritis damage and degenerative discs. For more information and scheduling call (888) 828-4575. Back pain due to spinal arthritis and degenerative disc disease affects tens of millions of Americans. Typical treatments are often effective but do not actually repair the damage present. Regenerative medicine treatments on the other hand, have the potential to repair the damage from degenerative disc disease and spinal arthritis. The Board Certified US doctors at TeleHealth have decades of experience in regenerative medicine treatments. With more published studies showing effectiveness of stem cell therapy for arthritis, receiving treatment for one's back condition may not only relieve pain but help eliminate the need for surgery and get patients back to work and playing with one's kids. Along with offering stem cell injections for back pain, TeleHealth also offers stem cell therapy for knee, shoulder, hip, ankle, and wrist arthritis along with rotator cuff and achilles tendonitis. Essentially any extremity arthritis along with … Continue reading →

HAIFA, Israel, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company will be actively participating in the Stem Cell Meeting on the Mesa on October 14-16, 2013. William R. Prather RPh, MD, Pluristem's Senior Vice President of Corporate Development will deliver a corporate presentation on Pluristem on October 14th at 5 pm PT. Additionally, Dr. Prather will be presenting a scientific poster on October 16th titled, "PLacental eXpanded (PLX) Cell Treatment Ameliorates Toll-like Receptor-Mediated Preeclampsia in Mice". The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field. About Pluristem Therapeutics Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are … Continue reading →

NEW YORK & PETACH TIKVAH, Israel--(BUSINESS WIRE)-- BrainStorm Cell Therapeutics (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it will initiate a pre-clinical study for Multiple Sclerosis (MS) at the Hebrew University Hadassah Medical Centers SPF-grade animal laboratory in Jerusalem. The study was approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University. Based on promising pre-clinical data published by the Company's Chief Scientist, Prof. Daniel Offen of Tel Aviv University, BrainStorm will conduct further studies using the Experimental Autoimmune Encephalomyelitis (EAE) animal model to evaluate MS as an additional indication for its NurOwn technology. Professor Dimitrios Karussis and Dr. Ibrahim Kassis, who have published extensively on pre-clinical research using the EAE model, will be the Principal Investigators of the study. Prof. Karussis, a Key Opinion Leader in the field of MS, is Head of the multi-disciplinary MS Clinic and Center at Hadassah, member of the European Steering Committee for Bone Marrow Transplantation in MS, member of the Executive Board and Scientific Committee of the European School of Neuroimmunology (ESNI), and former board member of the European Council and Committee for Treatment and Research in MS. He has been … Continue reading →

Public release date: 15-Oct-2013 [ | E-mail | Share ] Contact: David McKeon dmckeon@nyscf.org 212-365-7440 New York Stem Cell Foundation NEW YORK, NY (October 15, 2013) The New York Stem Cell Foundation (NYSCF) announced today that Amy Wagers, PhD, Professor at Harvard University, will be the 2013 recipient of the NYSCF Robertson Stem Cell Prize, which has been awarded since 2011 for extraordinary achievements in translational stem cell research by a younger scientist. Dr. Wagers is the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University and an Early Career Scientist of the Howard Hughes Medical Institute. At Harvard, she leads an independent research program that focuses on the regulation and therapeutic potential of blood and muscle stem cells. "Dr. Wagers' groundbreaking research on the biology of blood and muscle forming stem cells has opened up an avenue for cures of degenerative diseases of the aged," said Susan L. Solomon, CEO and Co-founder of NYSCF. "Her work has the potential to impact treatment of diabetes, cancer, and muscular dystrophy among many other devastating conditions." As the population ages, therapies that delay or reverse degenerative changes associated with age are increasingly important. To date, few interventions show promise, … Continue reading →

Good stem cell companies will get the funding they need to bring their products to market, financial and medical executives said at this year's Stem Cell Meeting on the Mesa. Biotech companies continue to attract investor interest, speakers said at the meeting this week in La Jolla, pointing to a stream of biotech initial public offerings as well as purchases of biotechs by large pharmaceutical companies. However, there's a catch: Companies may get a lower value than they seek. The field of stem cell therapies, also known as regenerative medicine, is making the transition from pure science to clinical medicine. San Diego's Cytori Therapeutics is testing a device to harvest a patient's stem cells for treating heart diseases and repairing tissue defects. And in a much-watched trial, a cure for HIV infection is being tested by Sangamo BioSciences, based in Richmond. The challenge for stem cell companies is to convince investors that their science is actually geared toward products that can be sold, said Ted Roth, president of Newport Beach-based Roth Capital Partners. Compared with 20 years ago, investors are much more sophisticated and aren't dazzled by technology, he said. "How can you convince me this is not a science … Continue reading →

Newswise Michael J. Klag, MD, MPH, dean of the Johns Hopkins Bloomberg School of Public Health, will award the Deans Medal to Suzanne and Bob Wright, co-founders of Autism Speaks, for their worldwide advocacy on behalf of individuals with autism. The Deans Medal is the Bloomberg Schools highest honor and celebrates individuals who have made a significant contribution to the field of public health. The Wrights will be presented with the Deans Medal at the Bloomberg School in Baltimore, Md. on October 15 during the Inaugural Symposium for the Wendy Klag Center for Autism and Developmental Disabilities. Inspired by the challenges facing their grandson who suffers from autism, Suzanne and Bob Wright launched Autism Speaks, the worlds leading autism science and advocacy organization, in February of 2005. The organization is dedicated to funding research into the causes, prevention, treatments and a cure for autism, increasing awareness of autism spectrum disorders and advocating for the needs of individuals with autism and their families. In addition to funding research, Autism Speaks has created resources and programs including the Autism Speaks Autism Treatment Network, Autism Speaks Autism Genetic Resource Exchange and several other scientific and clinical programs. Notable awareness initiatives include the establishment … Continue reading →